Zarxio and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Zarxio (filgrastim-sndz), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Vitamin D, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Nosebleed when taking Zarxio. It is created by eHealthMe based on reports of 3,248 people who have side effects when taking Zarxio from the FDA, and is updated regularly.

What is Zarxio?

Zarxio has active ingredients of filgrastim-sndz. eHealthMe is studying from 3,250 Zarxio users. Check the latest studies of Zarxio.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,080 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 16, 2026

3,248 people reported to have side effects when taking Zarxio.
Among them, 16 people (0.49%) have Nosebleed.

Among these 16 people:

How long have people been on Zarxio when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Zarxio? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Nosebleed when taking Zarxio? *

What are other drugs people take besides Zarxio? *

What are other side effects people have besides Nosebleed? *

Weakness: 4 people, 25.00%
Thrombocytopenia (decrease of platelets in blood): 4 people, 25.00%
Fever: 4 people, 25.00%
Confusional State: 4 people, 25.00%
Dysstasia (difficulty in standing): 4 people, 25.00%
Dyspnea (difficult or laboured breathing): 3 people, 18.75%
Peripheral Swelling: 3 people, 18.75%
Death: 3 people, 18.75%
Arrhythmias (irregular heartbeat): 3 people, 18.75%
Fatigue (feeling of tiredness): 3 people, 18.75%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 6 people, 37.50%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 18.75%
Insomnia (sleeplessness): 2 people, 12.50%
Diffuse Large B-Cell Lymphoma Recurrent (recurrent cancer of b cells, a type of white blood cell): 2 people, 12.50%
Dry Eyes (lack of adequate tears): 2 people, 12.50%
Dry Skin: 2 people, 12.50%
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 2 people, 12.50%
Infection: 2 people, 12.50%
Agitation (state of anxiety or nervous excitement): 2 people, 12.50%
Muscle Spasms (muscle contraction): 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Zarxio and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zarxio:

Zarxio (3,250 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Zarxio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,080 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,093 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on filgrastim-sndz (the active ingredients of Zarxio) and Zarxio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.